Baorui Liu

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo

Xianchuang Zheng, Xin Wang, Hui Mao et al. · Nature Communications · 2015 · 359 citations · Full text

Medicine, Cancer Biology, Oncology +17

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Shu Su, Bian Hu, Jie Shao et al. · Scientific Reports · 2016 · 303 citations · Full text

Life Sciences, Immunology, Oncology +17

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors

Fangjun Chen, Zhengyun Zou, Juan Du et al. · Journal of Clinical Investigation · 2019 · 228 citations · Full text

Life Sciences, Immunology, Oncology +17

Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia

Xianchuang Zheng, Hui Mao, Da Huo et al. · Nature Biomedical Engineering · 2017 · 210 citations

Medicine, Biomedical Engineering, Oncology +14